Biogen Biogen Idec, maker of the multiple sclerosis drug Tecfidera, fell after the stock was cut to “neutral” from “buy” at Citigroup. The stock had rallied 52 percent this year through Tuesday, Bloomberg News reported. Citi’s analyst cited concerns about regulatory protections for Tecfidera in the European Union when other drug makers submit applications to make generic versions. Full story for BostonGlobe.com subscribers.
This is a summary. To read the whole story subscribe to BostonGlobe.com
© Copyright 2014 Globe Newspaper Company.
Get the full story with unlimited access to BostonGlobe.com. Just 99¢ for 4 weeks.